NDC 63323-137 Bleomycin

Bleomycin Sulfate

NDC Product Code 63323-137

NDC CODE: 63323-137

Proprietary Name: Bleomycin What is the Proprietary Name?
The proprietary name also known as the trade name is the name of the product chosen by the medication labeler for marketing purposes.

Non-Proprietary Name: Bleomycin Sulfate What is the Non-Proprietary Name?
The non-proprietary name is sometimes called the generic name. The generic name usually includes the active ingredient(s) of the product.

Drug Use Information

Drug Use Information
The drug use information is a summary and does NOT have all possible information about this product. This information does not assure that this product is safe, effective, or appropriate. This information is not individual medical advice and does not substitute for the advice of a health care professional. Always ask a health care professional for complete information about this product and your specific health needs.

  • Bleomycin is used to treat cancer. It works by slowing or stopping the growth of cancer cells. This medication may also be used to control the build-up of fluid around the lungs (pleural effusion) caused by tumors that have spread to the lungs. For this condition, bleomycin is placed in the space around the lungs through a chest tube.

NDC Code Structure

  • 63323 - Fresenius Kabi Usa, Llc

NDC 63323-137-20


NDC Product Information

Bleomycin with NDC 63323-137 is a a human prescription drug product labeled by Fresenius Kabi Usa, Llc. The generic name of Bleomycin is bleomycin sulfate. The product's dosage form is injection, powder, lyophilized, for solution and is administered via intramuscular; intrapleural; intravenous; subcutaneous form. The RxNorm Crosswalk for this NDC code indicates multiple RxCUI concepts are associated to this product: 1726673 and 1726676.

Dosage Form: Injection, Powder, Lyophilized, For Solution - A dosage form intended for the solution prepared by lyophilization ("freeze drying"), a process which involves the removal of water from products in the frozen state at extremely low pressures; this is intended for subsequent addition of liquid to create a solution that conforms in all respects to the requirements for Injections.

Product Type: Human Prescription Drug What kind of product is this?
Indicates the type of product, such as Human Prescription Drug or Human Over the Counter Drug. This data element matches the “Document Type” field of the Structured Product Listing.

Bleomycin Active Ingredient(s)

What is the Active Ingredient(s) List?
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.

Administration Route(s)

What are the Administration Route(s)?
The translation of the route code submitted by the firm, indicating route of administration.

  • Intramuscular - Administration within a muscle.
  • Intrapleural - Administration within the pleura.
  • Intravenous - Administration within or into a vein or veins.
  • Subcutaneous - Administration beneath the skin; hypodermic. Synonymous with the term SUBDERMAL.

Pharmacological Class(es)

What is a Pharmacological Class?
These are the reported pharmacological class categories corresponding to the SubstanceNames listed above.

  • Cytoprotective Agent - [EPC] (Established Pharmacologic Class)

Product Labeler Information

What is the Labeler Name?
Name of Company corresponding to the labeler code segment of the Product NDC.

Labeler Name: Fresenius Kabi Usa, Llc
Labeler Code: 63323
FDA Application Number: ANDA065185 What is the FDA Application Number?
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.

Marketing Category: ANDA - A product marketed under an approved Abbreviated New Drug Application. What is the Marketing Category?
Product types are broken down into several potential Marketing Categories, such as NDA/ANDA/BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Start Marketing Date: 02-13-2009 What is the Start Marketing Date?
This is the date that the labeler indicates was the start of its marketing of the drug product.

Listing Expiration Date: 12-31-2021 What is the Listing Expiration Date?
This is the date when the listing record will expire if not updated or certified by the product labeler.

Exclude Flag: N - NO What is the NDC Exclude Flag?
This field indicates whether the product has been removed/excluded from the NDC Directory for failure to respond to FDA"s requests for correction to deficient or non-compliant submissions ("Y"), or because the listing certification is expired ("E"), or because the listing data was inactivated by FDA ("I"). Values = "Y", "N", "E", or "I".

* Please review the disclaimer below.

Information for Patients


Bleomycin is pronounced as (blee'' oh mye' sin)

Why is bleomycin medication prescribed?
Bleomycin injection is used alone or in combination with other medications to treat head and neck cancer (including cancer of the mouth, lip, cheek, tongue, palate, throa...
[Read More]

* Please review the disclaimer below.

Bleomycin Product Labeling Information

The product labeling information includes all published material associated to a drug. Product labeling documents include information like generic names, active ingredients, ingredient strength dosage, routes of administration, appearance, usage, warnings, inactive ingredients, etc.

Product Labeling Index


Rx only

Vascular toxicities coincident with the use of bleomycin in combination with other antineoplastic agents have been reported.  The events are clinically heterogeneous and may include myocardial infarction, cerebrovascular accident, thrombotic microangiopathy (HUS), or cerebral arteritis.  Various mechanisms have been proposed for these vascular complications.  There are also reports of Raynaud’s phenomenon occurring in patients treated with bleomycin in combination with vinblastine with or without cisplatin or, in a few cases, with bleomycin as a single agent.  It is currently unknown if the cause of Raynaud’s phenomenon in these cases is the disease, underlying vascular compromise, bleomycin, vinblastine, hypomagnesemia, or a combination of any of these factors.Fever, chills, and vomiting have been reported.  Anorexia and weight loss have been reported and may persist long after termination of this medication.  Pain at tumor site, phlebitis, and other local reactions have been reported. Malaise has been reported.

Www.fresenius-kabi.us45998F Revised: November 2016

Boxed Warning

It is recommended that Bleomycin for Injection, USP be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents.  Appropriate management of therapy and complications is possible only when adequate diagnostic and treatment facilities are readily available.Pulmonary fibrosis is the most severe toxicity associated with bleomycin.  The most frequent presentation is pneumonitis occasionally progressing to pulmonary fibrosis.  Its occurrence is higher in elderly patients and in those receiving greater than 400 units total dose, but pulmonary toxicity has been observed in young patients and those treated with low doses.A severe idiosyncratic reaction consisting of hypotension, mental confusion, fever, chills, and wheezing has been reported in approximately 1% of lymphoma patients treated with bleomycin.


Bleomycin for Injection, USP is a mixture of cytotoxic glycopeptide antibiotics isolated from a strain of Streptomyces verticillus.  It is freely soluble in water.Bleomycin for Injection, USP is provided as a sterile lyophilized powder for reconstitution containing 15 units per vial and 30 units per vial, which are intended for intramuscular, intravenous, subcutaneous or intrapleural administration.Its chemical name is N’-[3-(dimethylsulphonio)propyl]bleomycin-amide (bleomycin A2) and N’-[4-(guaniodobutyl)]bleomycin-amide (bleomycin B2). (Main component:  Bleomycin A2, in which R is [CH3]2S+CH2CH2CH2-)Note: A unit of bleomycin is equal to the formerly used milligram activity.  The term milligram activity is a misnomer and was changed to units to be more precise.

Mechanism Of Action

Although the exact mechanism of action of bleomycin is unknown, available evidence indicates that the main mode of action is the inhibition of DNA synthesis with some evidence of lesser inhibition of RNA and protein synthesis.Bleomycin is known to cause single, and to a lesser extent, double-stranded breaks in DNA.  In in vitro and in vivo experiments, bleomycin has been shown to cause cell cycle arrest in G2 and in mitosis. When administered into the pleural cavity in the treatment of malignant pleural effusion, bleomycin acts as a sclerosing agent.


AbsorptionBleomycin is rapidly absorbed following either intramuscular, subcutaneous, intraperitoneal, or intrapleural administration reaching peak plasma concentrations in 30 to 60 minutes.  Systemic bioavailability of bleomycin is 100% and 70% following intramuscular and subcutaneous administrations, respectively, and 45% following both intraperitoneal and intrapleural administrations, compared to intravenous and bolus administration.Following intramuscular doses of 1 to 10 units/m2, both peak plasma concentration and AUC increased in proportion with the increase of dose.Following intravenous bolus administration of 30 units of bleomycin to one patient with a primary germ cell tumor of the brain, a peak CSF level was 40% of the simultaneously-obtained plasma level and was attained in 2 hours after drug administration.  The area under the bleomycin CSF concentration x time curve was 25% of the area of the bleomycin plasma concentration x time curve.DistributionBleomycin is widely distributed throughout the body with a mean volume of distribution of 17.5 L/m2 in patients following a 15 units/m2 intravenous bolus dose.  Protein binding of bleomycin has not been studied. MetabolismBleomycin is inactivated by a cytosolic cysteine proteinase enzyme, bleomycin hydrolase.  The enzyme is widely distributed in normal tissues with the exception of the skin and lungs, both targets of bleomycin toxicity.  Systemic elimination of the drug by enzymatic degradation is probably only important in patients with severely compromised renal function.ExcretionThe primary route of elimination is via the kidneys.  About 65% of the administered intravenous dose is excreted in urine within 24 hours.  In patients with normal renal function, plasma concentrations of bleomycin decline biexponentially with a mean terminal half-life of 2 hours following intravenous bolus administration.  Total body clearance and renal clearance averaged 51 mL/min/m2 and 23 mL/min/m2, respectively.Following intrapleural administration to patients with normal renal function, a lower percentage of drug (40%) is recovered in the urine, as compared to that found in the urine after intravenous administration.Special PopulationsAge, Gender, and RaceThe effects of age, gender, and race on the pharmacokinetics of bleomycin have not been evaluated.PediatricChildren of less than 3 years of age have higher total body clearance than in adults, 71 mL/min/m2 versus 51 mL/min/m2, respectively, following intravenous bolus administration.  Children of more than 8 years of age have comparable clearance as in adults.In children with normal renal function, plasma concentrations of bleomycin decline biexponentially as in adults.  The volume of distribution and terminal half-life of bleomycin in children appears comparable to that in adults. Renal InsufficiencyRenal insufficiency markedly alters bleomycin elimination.  The terminal elimination half-life increases exponentially as the creatinine clearance decreases.  Dosing reductions were proposed for patients with creatinine clearance values of <50 mL/min (see PRECAUTIONS and DOSAGE AND ADMINISTRATION).Hepatic InsufficiencyThe effect of hepatic insufficiency on the pharmacokinetics of bleomycin has not been evaluated.Drug InteractionsDrugs that Can Affect Renal ClearanceBecause bleomycin is eliminated predominantly through renal excretion, the administration of nephrotoxic drugs with bleomycin may affect its renal clearance.  Specifically, in one report of 2 children receiving concomitant cisplatin with bleomycin, total body clearance of bleomycin decreased from 39 to 18 mL/min/m2 as the cumulative dose of cisplatin exceeded 300 mg/m2.  Terminal half-life of bleomycin also increased from 4.4 to 6 hours.  Fatal bleomycin pulmonary toxicity has been reported in a patient with unrecognized cisplatin-induced oliguric renal failure.

Clinical Studies

Malignant Pleural EffusionThe safety and efficacy of bleomycin 60 units and tetracycline (1 g) as treatment for malignant pleural effusion were evaluated in a multicenter, randomized trial.  Patients were required to have cytologically positive pleural effusion, good performance status (0,1,2), lung re-expansion following tube thoracostomy with drainage rates of 100 mL/24 hours or less, no prior intrapleural therapy, no prior systemic bleomycin therapy, no chest irradiation, and no recent change in systemic therapy.  Overall survival did not differ between the bleomycin (n=44) and tetracycline treatment (n=41) groups.  Of patients evaluated within 30 days of instillation, the recurrence rate was 36% (10/28) with bleomycin and 67% (18/27) with tetracycline (p=0.023).  Toxicity was similar between groups.

Indications And Usage:

Bleomycin for Injection, USP should be considered a palliative treatment.  It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: Squamous Cell Carcinoma: Head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva.  The response to Bleomycin for Injection is poorer in patients with previously irradiated head and neck cancer.Lymphomas: Hodgkin’s disease, non-Hodgkin’s lymphoma.Testicular Carcinoma: Embryonal cell, choriocarcinoma, and teratocarcinoma.Bleomycin for Injection, USP has also been shown to be useful in the management of:Malignant Pleural Effusion: Bleomycin for Injection is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions.


Bleomycin for Injection is contraindicated in patients who have demonstrated a hypersensitive or an idiosyncratic reaction to it.


Patients receiving bleomycin must be observed carefully and frequently during and after therapy.  It should be used with extreme caution in patients with significant impairment of renal function or compromised pulmonary function.Pulmonary toxicities occur in 10% of treated patients.  In approximately 1%, the nonspecific pneumonitis induced by bleomycin progresses to pulmonary fibrosis and death. Although this is age and dose related, the toxicity is unpredictable.  Frequent roentgenograms are recommended (see ADVERSE REACTIONS, Pulmonary).A severe idiosyncratic reaction (similar to anaphylaxis) consisting of hypotension, mental confusion, fever, chills, and wheezing has been reported in approximately 1% of lymphoma patients treated with bleomycin.  Since these reactions usually occur after the first or second dose, careful monitoring is essential after these doses (see ADVERSE REACTIONS, Idiosyncratic Reactions).Renal or hepatic toxicity, beginning as a deterioration in renal or liver function tests, have been reported.  These toxicities may occur at any time after initiation of therapy.

Usage In Pregnancy

Pregnancy “Category D”Bleomycin can cause fetal harm when administered to a pregnant woman.  It has been shown to be teratogenic in rats.  Administration of intraperitoneal doses of 1.5 mg/kg/day to rats (about 1.6 times the recommended human dose on a unit/m2 basis) on days 6 to 15 of gestation caused skeletal malformations, shortened innominate artery and hydroureter. Bleomycin is abortifacient but not teratogenic in rabbits at intravenous doses of 1.2 mg/kg/day (about 2.4 times the recommended human dose on a unit/m2 basis) given on gestation days 6 to 18.There have been no studies in pregnant women.  If bleomycin is used during pregnancy, or if the patient becomes pregnant while receiving this drug, the patient should be apprised of the potential hazard to the fetus.  Women of childbearing potential should be advised to avoid becoming pregnant during therapy with bleomycin.


Patients with creatinine clearance values of less than 50 mL/min should be treated with caution and their renal function should be carefully monitored during the administration of bleomycin.  Lower doses of bleomycin may be required in these patients than those with normal renal function (see CLINICAL PHARMACOLOGY and DOSAGE AND ADMINISTRATION).

Carcinogenesis, Mutagenesis, Impairment Of Fertility

The carcinogenic potential of bleomycin in humans is unknown.  A study in F344-type male rats demonstrated an increased incidence of nodular hyperplasia after induced lung carcinogenesis by nitrosamines, followed by treatment with bleomycin.  In another study where the drug was administered to rats by subcutaneous injection at 0.35 mg/kg weekly (3.82 units/m2 weekly or about 30% at the recommended human dose), necropsy findings included dose-related injection site fibrosarcomas as well as various renal tumors. Bleomycin has been shown to be mutagenic both in vitro and in vivo.  The effects of bleomycin on fertility have not been studied.


Pregnancy “Category D”(See WARNINGS.)

Nursing Mothers

It is not known whether the drug is excreted in human milk.  Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants, it is recommended that nursing be discontinued by women receiving bleomycin therapy.

Pediatric Use

Safety and effectiveness of bleomycin in pediatric patients have not been established.

Geriatric Use

In clinical trials, pulmonary toxicity was more common in patients older than 70 years than in younger patients (see BOXED WARNING, WARNINGS, and ADVERSE REACTIONS, Pulmonary).  Other reported clinical experience has not identified other differences in responses between elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out.Bleomycin is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function.  Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.


The most serious side effects are pulmonary adverse reactions, occurring in approximately 10% of treated patients.  The most frequent presentation is pneumonitis occasionally progressing to pulmonary fibrosis.  Approximately 1% of patients treated have died of pulmonary fibrosis.  Pulmonary toxicity is both dose and age related, being more common in patients over 70 years of age and in those receiving over 400 units total dose.  This toxicity, however, is unpredictable and has been seen in young patients receiving low doses.  Some published reports have suggested that the risk of pulmonary toxicity may be increased when bleomycin is used in combination with G-CSF (filgrastim) or other cytokines.  However, randomized clinical studies completed to date have not demonstrated an increased risk of pulmonary complications in patients treated with bleomycin and G-CSF.Because of lack of specificity of the clinical syndrome, the identification of patients with pulmonary toxicity due to bleomycin has been extremely difficult.  The earliest symptom associated with bleomycin pulmonary toxicity is dyspnea.  The earliest sign is fine rales.Radiographically, bleomycin-induced pneumonitis produces nonspecific patchy opacities, usually of the lower lung fields.  The most common changes in pulmonary function tests are a decrease in total lung volume and a decrease in vital capacity. However, these changes are not predictive of the development of pulmonary fibrosis. The microscopic tissue changes due to bleomycin toxicity include bronchiolar squamous metaplasia, reactive macrophages, atypical alveolar epithelial cells, fibrinous edema, and interstitial fibrosis.  The acute stage may involve capillary changes and subsequent fibrinous exudation into alveoli producing a change similar to hyaline membrane formation and progressing to a diffuse interstitial fibrosis resembling the Hamman-Rich syndrome.  These microscopic findings are nonspecific; e.g., similar changes are seen in radiation pneumonitis and pneumocystic pneumonitis.To monitor the onset of pulmonary toxicity, roentgenograms of the chest should be taken every 1 to 2 weeks (see WARNINGS).  If pulmonary changes are noted, treatment should be discontinued until it can be determined if they are drug related.  Recent studies have suggested that sequential measurement of the pulmonary diffusion capacity for carbon monoxide (DLco) during treatment with bleomycin may be an indicator of subclinical pulmonary toxicity.  It is recommended that the DLco be monitored monthly if it is to be employed to detect pulmonary toxicities, and thus the drug should be discontinued when the DLco falls below 30% to 35% of the pretreatment value.Because of bleomycin’s sensitization of lung tissue, patients who have received bleomycin are at greater risk of developing pulmonary toxicity when oxygen is administered in surgery.  While long exposure to very high oxygen concentrations is a known cause of lung damage, after bleomycin administration, lung damage can occur at lower concentrations that are usually considered safe.  Suggested preventive measures are:    1.  Maintain FlO2 at concentrations approximating that of room air (25%) during surgery and the postoperative period.    2.  Monitor carefully fluid replacement, focusing more on colloid administration rather than crystalloid.Sudden onset of an acute chest pain syndrome suggestive of pleuropericarditis has been reported during bleomycin infusions.  Although each patient must be individually evaluated, further courses of bleomycin do not appear to be contraindicated.Pulmonary adverse events which may be related to the intrapleural administration of bleomycin have been reported.

Idiosyncratic Reactions

In approximately 1% of the lymphoma patients treated with bleomycin, an idiosyncratic reaction, similar to anaphylaxis clinically, has been reported.  The reaction may be immediate or delayed for several hours, and usually occurs after the first or second dose (see WARNINGS).  It consists of hypotension, mental confusion, fever, chills, and wheezing.  Treatment is symptomatic including volume expansion, pressor agents, antihistamines, and corticosteroids.

Integument And Mucous Membranes

These adverse reactions have been reported in approximately 50% of treated patients.  They consist of erythema, rash, striae, vesiculation, hyperpigmentation, and tenderness of the skin.  Hyperkeratosis, nail changes, alopecia, pruritus, and stomatitis have also been reported.  It was necessary to discontinue bleomycin therapy in 2% of treated patients because of these toxicities.Scleroderma-like skin changes have been reported.Skin toxicity is a relatively late manifestation usually developing in the second and third week of treatment after 150 to 200 units of bleomycin have been administered and appears to be related to the cumulative dose.Intrapleural administration of bleomycin has been associated with local pain.  Hypotension possibly requiring symptomatic treatment has been reported.  Death has been reported in association with bleomycin pleurodesis in seriously ill patients.

Dosage And Administration:

Because of the possibility of an anaphylactoid reaction, lymphoma patients should be treated with 2 units or less for the first 2 doses.  If no acute reaction occurs, then the regular dosage schedule may be followed.The following dose schedule is recommended: Squamous cell carcinoma, non-Hodgkin’s lymphoma, testicular carcinoma– 0.25 to 0.5 units/kg (10 to 20 units/m2) given intravenously, intramuscularly, or subcutaneously weekly or twice weekly.Hodgkin’s Disease– 0.25 to 0.5 units/kg (10 to 20 units/m2) given intravenously, intramuscularly, or subcutaneously weekly or twice weekly.  After a 50% response, a maintenance dose of 1 unit daily or 5 units weekly intravenously or intramuscularly should be given.Pulmonary toxicity of Bleomycin for Injection, USP appears to be dose-related with a striking increase when the total dose is over 400 units.  Total doses over 400 units should be given with great caution.Note: When Bleomycin for Injection, USP is used in combination with other antineoplastic agents, pulmonary toxicities may occur at lower doses.Improvement of Hodgkin’s disease and testicular tumors is prompt and noted within 2 weeks.  If no improvement is seen by this time, improvement is unlikely. Squamous cell cancers respond more slowly, sometimes requiring as long as 3 weeks before any improvement is noted.Malignant Pleural Effusion– 60 units administered as a single dose bolus intrapleural injection (see ADMINISTRATION, Intrapleural).Use in Patients with Renal InsufficiencyThe following dosing reductions are proposed for patients with creatinine clearance (CrCL) values of less than 50 mL/min: Patient CrCL(mL/min)  Bleomycinfor Injection, USPDose (%)  50 and above  100  40 to 50  70  30 to 40  60  20 to 30  55  10 to 20  45  5 to 10  40 CrCL can be estimated from the individual patient’s measured serum creatinine (Scr) values using the Cockcroft and Gault formula:Males    CrCL = [weight x (140 – Age)]/(72 x Scr)Females CrCL = 0.85 x [weight x (140 – Age)]/(72 x Scr)Where CrCL in mL/min/1.73 m2, weight in kg, age in years, and Scr in mg/dL.


Bleomycin for Injection may be given by the intramuscular, intravenous, subcutaneous, or intrapleural routes.

Administration Precautions

Caution should be exercised when handling Bleomycin for Injection.  Procedures for proper handling and disposal of anticancer drugs should be utilized.  Several guidelines on this subject have been published.1-4  To minimize the risk of dermal exposure, always wear impervious gloves when handling vials containing Bleomycin for Injection.  If Bleomycin for Injection contacts the skin, immediately wash the skin thoroughly with soap and water.  If contact with mucous membranes occurs, the membranes should be flushed immediately and thoroughly with water.  More information is available in the references listed below.

Intramuscular Or Subcutaneous

The Bleomycin for Injection 15 units vial should be reconstituted with 1 to 5 mL of Sterile Water for Injection, USP, Sodium Chloride for Injection, 0.9%, USP, or Sterile Bacteriostatic Water for Injection, USP.  The Bleomycin for Injection 30 units vial should be reconstituted with 2 to 10 mL of the above diluents.


The contents of the 15 units or 30 units vial should be dissolved in 5 mL or 10 mL, respectively, of Sodium Chloride for Injection, 0.9%, USP, and administered slowly over a period of 10 minutes.


Sixty units of Bleomycin for Injection are dissolved in 50 to 100 mL Sodium Chloride for Injection, 0.9%, USP, and administered through a thoracostomy tube following drainage of excess pleural fluid and confirmation of complete lung expansion.  The literature suggests that successful pleurodesis is, in part, dependent upon complete drainage of the pleural fluid and re-establishment of negative intrapleural pressure prior to instillation of a sclerosing agent.  Therefore, the amount of drainage from the chest tube should be as minimal as possible prior to instillation of Bleomycin for Injection.  Although there is no conclusive evidence to support this contention, it is generally accepted that chest tube drainage should be less than 100 mL in a 24-hour period prior to sclerosis.  However, Bleomycin for Injection instillation may be appropriate when drainage is between 100 to 300 mL under clinical conditions that necessitate sclerosis therapy.  The thoracostomy tube is clamped after Bleomycin for Injection instillation.  The patient is moved from the supine to the left and right lateral positions several times during the next four hours.  The clamp is then removed and suction re-established.  The amount of time the chest tube remains in place following sclerosis is dictated by the clinical situation.The intrapleural injection of topical anesthetics or systemic narcotic analgesia is generally not required. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

How Supplied:

Bleomycin for Injection, USP is available as follows: ProductNo.NDCNo.10361063323-136-10  15 units per vial, individually packaged.10372063323-137-2030 units per vial, individually packaged.


The sterile powder is stable under refrigeration 2°C to 8°C (36°F to 46°F) and should not be used after the expiration date is reached.Bleomycin for Injection should not be reconstituted or diluted with D5W or other dextrose containing diluents.  When reconstituted in D5W and analyzed by HPLC, Bleomycin for Injection demonstrates a loss of A2 and B2 potency that does not occur when Bleomycin for Injection is reconstituted in Sodium Chloride for Injection, 0.9%, USP. Bleomycin for Injection is stable for 24 hours at room temperature in Sodium Chloride.The container closure is not made with natural rubber latex.


  • NIOSH Alert: Preventing occupational exposures to antineoplastic and other hazardous drugs in healthcare settings. 2004. U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, DHHS (NIOSH) Publication No. 2004-165.OSHA Technical Manual, TED 1-0.15A, Section VI: Chapter 2. Controlling occupational exposure to hazardous drugs. OSHA, 1999. http://www.osha.gov/dts/osta/otm/otm_vi/otm_vi_2.htmlAmerican Society of Health-System Pharmacists. ASHP guidelines on handling hazardous drugs. Am J Health-Syst Pharm. 2006;63:1172-1193.Polovich M, White JM, Kelleher LO, eds. 2005. Chemotherapy and biotherapy guidelines and recommendations for practice. 2nd ed. Pittsburgh, PA: Oncology Nursing Society.

* Please review the disclaimer below.